first large study of glp-1 receptor agonists during pregnancy Glucagon-like peptide-1 agonist use in pregnancy: a review Frontiers | Effects of GLP-1

Tracking cognitive effects Subjective assessment provides useful but limited information

Ul Haq I, Krukiewicz K, Yahya G, et al

Tesamorelin vs CJC-1295/Ipamorelin at a Glance Tesamorelin FDA Status FDA-approved (Egrifta, November 2010) CJC-1295/Ipam FDA Status Compounded (CJC-1295 reached Phase 2) Tesamorelin Mechanism GHRH receptor only (DPP-IV protected) CJC-1295/Ipam Mechanism GHRH + ghrelin receptor (dual pathway) Strongest Evidence Tesamorelin: 2 Phase 3 RCTs, 816 patients, CT-measured fat Most Popular CJC-1295/Ipamorelin (dual pathway, broader benefits) The Core Difference Tesamorelin and CJC-1295 both bind the GHRH receptor on pituitary somatotroph cells to stimulate growth hormone release

BPC-157